An AI algorithm for breast cancer screening has potential to enhance the performance of digital breast tomosynthesis (DBT), reducing interval cancers by up to one-third, according to a new study.

The glycocalyx surrounds each cell in the human body like a coat. This complex sugar layer plays a key role in the progression of numerous diseases, such as cancer and autoimmune diseases. Researchers at the Max Planck Institute for the Science of Light (MPL) have succeeded for the first time in imaging individual sugars within the glycocalyx at molecular resolution and linking their spatial arrangement to their biological function. The findings, recently published in the journal Nature Nanotechnology, open up completely new perspectives for understanding this important cell structure – with far-reaching consequences for diagnosis and therapy.

BUFFALO, NY – July 29, 2025 – A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled “Comprehensive genomic profiling of over 10,000 advanced solid tumors.”

New research identifies NF-kappa-B-activating protein-like (NKAPL) as a potent tumor suppressor in non-small cell lung cancer (NSCLC).

Aging immune cells known as senescent macrophages are emerging as critical players in cancer progression.

Oak Brook, IL – Volume 34 of SLAS Discovery includes two original research articles, one short communication and one entry in the upcoming Special Issue on EUOS/SLAS Joint Challenge: Compound Solubility.

Despite significant advancements in biosensing technologies, the early and accurate diagnosis of cancer remains challenging. In a recent study, researchers from Japan have developed a novel microfluidic device containing arrays of microcones to detect cancer cells in the blood. Their device leverages cancer-specific antibodies as coatings to accurately detect cancer cells. Furthermore, the microchannel device maintained a high capture efficiency of more than 90%, even at high flow rates.

Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment — immunotherapy — may help change the environment where cancer cells live, possibly helping the immune system respond more effectively.